secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001104659-22-040209
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics CEO Lucy Lu resigns; COO David Jin becomes interim principal executive officer
--------------------------------------------------------------------------------

- Lucy Lu, M.D. resigned as President, CEO, and Board member effective March 31, 2022, to pursue an outside opportunity.
- She entered into a consulting arrangement with the Company effective March 31, 2022.
- David Jin, previously COO, will serve as interim principal executive officer from March 31, 2022.
- Company continues evaluating potential strategic transaction options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/0001104659-22-040209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922040209/tm2210898d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-040209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer